IDORSIA AG
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commer… Read more
IDORSIA AG (19T) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.031x
Based on the latest financial reports, IDORSIA AG (19T) has a cash flow conversion efficiency ratio of 0.031x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-35.26 Million) by net assets (€-1.14 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
IDORSIA AG - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how IDORSIA AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
IDORSIA AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IDORSIA AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MultiChoice Group Ltd
PINK:MCOIF
|
0.343x |
|
Salzgitter AG
PINK:SZGPF
|
0.053x |
|
Hunan Aerospace Huanyu Communication Technology Co. Ltd. A
SHG:688523
|
N/A |
|
Zhuhai Enpower Electric Co Ltd
SHE:300681
|
0.046x |
|
Ethan Allen Interiors Inc
NYSE:ETD
|
0.027x |
|
Quanta Storage
TWO:6188
|
-0.024x |
|
Xiamen Jihong Package Technology Ltd
SHE:002803
|
-0.014x |
|
Gas Malaysia Bhd
KLSE:5209
|
0.049x |
Annual Cash Flow Conversion Efficiency for IDORSIA AG (2021–2024)
The table below shows the annual cash flow conversion efficiency of IDORSIA AG from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-1.21 Billion | €-370.23 Million | 0.305x | -52.98% |
| 2023-12-31 | €-968.72 Million | €-629.30 Million | 0.650x | -50.02% |
| 2022-12-31 | €-660.96 Million | €-859.11 Million | 1.300x | +122.96% |
| 2021-12-31 | €104.20 Million | €-589.89 Million | -5.661x | -- |